Wed, Apr 26, 2017
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

Lyxor Research: More upside in 2013 for hedge funds

Wednesday, July 17, 2013
Opalesque Industry Update - The remainder of 2013 is setting up for further gains and hedge funds are positioned to take advantage of the opportunities. The US economy is expanding steadily and growth will likely accelerate in the 2nd half of the year as fiscal restraint wears off. Markets have digested the higher move in bond yields and any further rise in yields will occur because of firmer economic data.

Central banks globally are almost unanimously dovish which should translate into asset reflation and easy financial conditions. The Bank of England and European Central Bank were the latest banks to use “lower for longer” language to drive down interest rates. Chairman Bernanke has also indicated that the Fed will hold rates at the current 0% level for the foreseeable future.

At the same time, economic data is improving. High velocity indicators in Europe such as PMI are increasing from a dip in 1Q and broad data in the US such as jobs, spending and production are also suggesting the economy is improving.

The volatility spike and risk aversion in June presents an attractive entry point and opportunity going forward. Risk premium increased because of higher rates and concerns about emerging markets. Both of these issues have stabilized. Bond yields in the US have repriced sharply since May but the pace of the increase will likely slow going forward. China concerns have also dissipated as the authorities introduced more liquidity into the market. We expect risk premium normalization to continue which translates into higher asset prices.

Equities are our favorite asset class and a key beneficiary of asset . Based on our metrics, equities are significantly more attractively valued than other assets at this stage in the cycle. Within equities, Japan is our most overweight region because it offers the best upside given the size of central bank stimulus and attractive valuation.

In our Alternative Strategies ranking, we have an overweight bias to directional strategies in the equity space. L/S Equity discretionary and systematic neutral strategies should benefit from a high dispersion, low volatility environment. We upgraded Long term CTAs to slight overweight after a challenging 2Q because we believe the factors responsible for the soft performance, such as a spike in rates, will be more benign going forward. On the credit side, the market appears richly valued and we downgraded L/S credit to neutral. We advocate focusing on relative value funds in the credit space with limited interest rate risk.. Based on our metrics, equities are significantly more attractively valued than other assets at this stage in the cycle. Within equities, Japan is our most overweight region because it offers the best upside given the size of central bank stimulus and attractive valuation.

In our Alternative Strategies ranking, we have an overweight bias to directional strategies in the equity space. L/S Equity discretionary and systematic neutral strategies should benefit from a high dispersion, low volatility environment. We upgraded Long term CTAs to slight overweight after a challenging 2Q because we believe the factors responsible for the soft performance, such as a spike in rates, will be more benign going forward. On the credit side, the market appears richly valued and we downgraded L/S credit to neutral. We advocate focusing on relative value funds in the credit space with limited interest rate risk.

References:
Lyxor AM, Cross Asset Research, Third Quarter 2013, www.lyxor.com

Bg

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing

 



  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Alternative asset firm YieldStreet surpasses $100m of loans funded in less than 8 quarters[more]

    Komfie Manalo, Opalesque Asia: Alternative asset investment platform YieldStreet reported that it has surpassed $100m in loans funded in less than eight quarters from accredited investors and single family offices. YieldStreet was founded by Milind Mehere and Michael Weisz. In a

  2. Investing - Investor appetite for high-growth IPOs to be tested, Apollo boosts fund's stock allowance for 'diamonds in the rough', Hedge funds uncertain over outlook for Hargreaves Lansdown[more]

    Investor appetite for high-growth IPOs to be tested From FT.com: The US listings market is poised for a busy week with deals that will test investors' appetite for high-growth - but lossmaking - companies. Eight new listings are scheduled for this week, the most since October of 2016,

  3. Hedge funds holding Puerto Rico bonds are looking at a long battle[more]

    Komfie Manalo, Opalesque Asia: Hedge funds which bought Puerto Rico's distressed debt bonds are facing the prospect of a long road ahead to recover their investments as the Caribbean island is attempting to use a U.S. Congress-approved rule that allows it to exploit a bankruptcy-like proceedings

  4. Other Voices: "Winner-take-all" dynamics and hedge fund investing[more]

    A growing stream of thinking in microeconomics is the concept of "winner-take-all" dynamics. The idea seems simple. A combination of networking economics and classic economies of scale creates situations where there are just a few dominant firms or economic agents who are able to capture significant

  5. Investing - How Chipotle's comeback attracted big data robots and value investors alike[more]

    From Forbes.com: When William Ackman's ailing hedge fund Pershing Square Capital Management bet $1 billion on shares in Chipotle Mexican Grill beginning in July 2016, the stakes couldn't have been higher. Pershing Square was reeling from what would eventually be a near $4 billion loss in drugmaker V